DAMORA THERAPEUTICS, INC. (DMRA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 27.55M USD | Liabilities, Current |
| Cash and equivalents | 540.51M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $27.55M | $540.51M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $23.81M | $532.90M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $20.07M | $257.62M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.62M | $7.61M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.63M | $10.21M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.55M | $11.94M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.20M | $14.18M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.44M | $19.68M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.71M | $22.86M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.32M | $21.09M | $6.08M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $5.83M | $21.46M | $11.69M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $12.55M | $23.08M | $21.10M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $14.90M | $22.96M | $29.17M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $14.06M | $25.07M | $28.18M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $11.11M | $32.79M | $27.44M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $8.86M | $28.34M | $40.75M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $7.49M | $29.80M | $49.23M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $7.21M | $45.39M | $48.21M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.54M | $62.56M | $37.63M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $5.74M | $66.16M | $35.99M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.75M | $68.64M | $33.18M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $5.54M | $74.25M | $36.08M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.57M | $163.58M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $8.28M | $85.33M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $35.84M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $42.78M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $7.93M | $11.29M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $14.70M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |